Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and ...

Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to advance cancer therapy ...

Updated presentation on Cogent’s potent pan-KRAS(ON) inhibitor, CGT1263, showcasing its selectivity profile which could lead to reduction in ...

The Parker Institute for Cancer Immunotherapy (PICI), today announced that research and expertise from across its network ...

WHAT: Researchers from the Johns Hopkins Kimmel Cancer Center will present new research findings and receive honors and ...

Tempus AI TEM shares are up on Tuesday as the company announced the acceptance of 31 abstracts for presentation at the ...

-- PanGIA Analysis System, a novel machine learning platform for non-invasive diagnosis of oral cancer through an oral sample -- PanGIA Analysis System, a novel machine learning platform for ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acceptance of 31 abstracts-including one oral presentation-for the ...

With new developments constantly happening in the field of targeted therapies for patients with lung cancer, it’s up to patients to make sure they are receiving up-to-date care precision care, ...

Lung cancer in general, and non-small cell lung cancer (NSCLC) in particular, is often asymptomatic in the early stages of the disease. When symptoms do occur in an early stage (e.g., endobronchial ...